ABIVAX Société Anonyme (ABVX)
- Previous Close
15.74 - Open
15.78 - Bid --
- Ask --
- Day's Range
15.06 - 16.00 - 52 Week Range
7.99 - 17.02 - Volume
53,721 - Avg. Volume
69,669 - Market Cap (intraday)
992.841M - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
-- - EPS (TTM)
-3.67 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.05
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
www.abivax.comRecent News: ABVX
Performance Overview: ABVX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABVX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABVX
Valuation Measures
Market Cap
1.00B
Enterprise Value
779.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.73
Enterprise Value/Revenue
157.63
Enterprise Value/EBITDA
-5.85
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.57%
Return on Equity (ttm)
-145.41%
Revenue (ttm)
4.49M
Net Income Avi to Common (ttm)
-147.74M
Diluted EPS (ttm)
-3.67
Balance Sheet and Cash Flow
Total Cash (mrq)
260.99M
Total Debt/Equity (mrq)
37.99%
Levered Free Cash Flow (ttm)
-57.41M